Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation

Constantinos T. Sofocleous, Sandeep K. Garg, Perry R. Cohen, Elena N. Petre, Mithat Gonen, Joseph P. Erinjeri, Robert J. Downey, William D. Travis, Stephen B. Solomon

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background. The objective of this work was to evaluate the feasibility of histopathological analysis of tissue extracted on multitined electrodes and assess whether tissue characteristics can be used as biomarkers of oncologic outcomes after lung tumor radiofrequency (RF) ablation. Methods. Treatment-related data regarding RF ablation of lung malignancies at our institution was collected using a Health Insurance Portability and Accountability Act-compliant ablation database. Institutional review board waiver was obtained for this study. Immunohistochemical analysis of tissue extracted from the electrodes after lung tumor RF ablation was performed for proliferation (Ki-67) and apoptosis (caspase-3). Patient, tumor demographics, and ablation parameters were recorded. Local tumor progression- free survival (LPFS), disease-specific survival (DSS), and overall survival (OS) were assessed using Kaplan- Meier methodology. Multivariate analysis determined factors affecting these oncological outcomes. Results. A total of 47 lung tumors in 42 patients were ablated; 30 specimens were classified as coagulation necrosis (CN) and 17 as Ki-67-positive (+) tumor cells (viable). Tumor sizes were similar in the CN and Ki-67+ groups (P = 0.32). Median LPFS was 10 versus 16 months for Ki-67+ and CN groups, and 1-year LPFS was 34 and 75 %, respectively (P = 0.003). Median OS was 20 and 46 months (P = 0.12), and median DSS was 20 and 68 months (P = 0.01) for the Ki-67 + and CN groups, respectively. Identification of Ki-67+ tumor cells more than tripled the risk of death from cancer [hazard ratio (HR) = 3.65; 95 % confidence interval (95 % CI), 1.34-9.95; P = 0.01] and tripled the risk of local tumor progression (LTP) (HR = 3.01; 95 % CI, 1.39-6.49; P = 0.005). Conclusions. Ki-67+ tumor cells on the electrode after pulmonary tumor RF ablation is an independent predictor of LTP, shorter LPFS, and DSS.

Original languageEnglish (US)
JournalAnnals of Surgical Oncology
Volume20
Issue number3 SUPPL.
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Tumor Biomarkers
Recurrence
Lung
Survival
Neoplasms
Disease-Free Survival
Necrosis
Electrodes
Confidence Intervals
Health Insurance Portability and Accountability Act
Research Ethics Committees
Caspase 3

ASJC Scopus subject areas

  • Surgery
  • Oncology
  • Medicine(all)

Cite this

Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation. / Sofocleous, Constantinos T.; Garg, Sandeep K.; Cohen, Perry R.; Petre, Elena N.; Gonen, Mithat; Erinjeri, Joseph P.; Downey, Robert J.; Travis, William D.; Solomon, Stephen B.

In: Annals of Surgical Oncology, Vol. 20, No. 3 SUPPL., 2013.

Research output: Contribution to journalArticle

Sofocleous, Constantinos T. ; Garg, Sandeep K. ; Cohen, Perry R. ; Petre, Elena N. ; Gonen, Mithat ; Erinjeri, Joseph P. ; Downey, Robert J. ; Travis, William D. ; Solomon, Stephen B. / Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation. In: Annals of Surgical Oncology. 2013 ; Vol. 20, No. 3 SUPPL.
@article{b705a98d40fe460cb15fed3d0717b156,
title = "Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation",
abstract = "Background. The objective of this work was to evaluate the feasibility of histopathological analysis of tissue extracted on multitined electrodes and assess whether tissue characteristics can be used as biomarkers of oncologic outcomes after lung tumor radiofrequency (RF) ablation. Methods. Treatment-related data regarding RF ablation of lung malignancies at our institution was collected using a Health Insurance Portability and Accountability Act-compliant ablation database. Institutional review board waiver was obtained for this study. Immunohistochemical analysis of tissue extracted from the electrodes after lung tumor RF ablation was performed for proliferation (Ki-67) and apoptosis (caspase-3). Patient, tumor demographics, and ablation parameters were recorded. Local tumor progression- free survival (LPFS), disease-specific survival (DSS), and overall survival (OS) were assessed using Kaplan- Meier methodology. Multivariate analysis determined factors affecting these oncological outcomes. Results. A total of 47 lung tumors in 42 patients were ablated; 30 specimens were classified as coagulation necrosis (CN) and 17 as Ki-67-positive (+) tumor cells (viable). Tumor sizes were similar in the CN and Ki-67+ groups (P = 0.32). Median LPFS was 10 versus 16 months for Ki-67+ and CN groups, and 1-year LPFS was 34 and 75 {\%}, respectively (P = 0.003). Median OS was 20 and 46 months (P = 0.12), and median DSS was 20 and 68 months (P = 0.01) for the Ki-67 + and CN groups, respectively. Identification of Ki-67+ tumor cells more than tripled the risk of death from cancer [hazard ratio (HR) = 3.65; 95 {\%} confidence interval (95 {\%} CI), 1.34-9.95; P = 0.01] and tripled the risk of local tumor progression (LTP) (HR = 3.01; 95 {\%} CI, 1.39-6.49; P = 0.005). Conclusions. Ki-67+ tumor cells on the electrode after pulmonary tumor RF ablation is an independent predictor of LTP, shorter LPFS, and DSS.",
author = "Sofocleous, {Constantinos T.} and Garg, {Sandeep K.} and Cohen, {Perry R.} and Petre, {Elena N.} and Mithat Gonen and Erinjeri, {Joseph P.} and Downey, {Robert J.} and Travis, {William D.} and Solomon, {Stephen B.}",
year = "2013",
doi = "10.1245/s10434-013-3140-1",
language = "English (US)",
volume = "20",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation

AU - Sofocleous, Constantinos T.

AU - Garg, Sandeep K.

AU - Cohen, Perry R.

AU - Petre, Elena N.

AU - Gonen, Mithat

AU - Erinjeri, Joseph P.

AU - Downey, Robert J.

AU - Travis, William D.

AU - Solomon, Stephen B.

PY - 2013

Y1 - 2013

N2 - Background. The objective of this work was to evaluate the feasibility of histopathological analysis of tissue extracted on multitined electrodes and assess whether tissue characteristics can be used as biomarkers of oncologic outcomes after lung tumor radiofrequency (RF) ablation. Methods. Treatment-related data regarding RF ablation of lung malignancies at our institution was collected using a Health Insurance Portability and Accountability Act-compliant ablation database. Institutional review board waiver was obtained for this study. Immunohistochemical analysis of tissue extracted from the electrodes after lung tumor RF ablation was performed for proliferation (Ki-67) and apoptosis (caspase-3). Patient, tumor demographics, and ablation parameters were recorded. Local tumor progression- free survival (LPFS), disease-specific survival (DSS), and overall survival (OS) were assessed using Kaplan- Meier methodology. Multivariate analysis determined factors affecting these oncological outcomes. Results. A total of 47 lung tumors in 42 patients were ablated; 30 specimens were classified as coagulation necrosis (CN) and 17 as Ki-67-positive (+) tumor cells (viable). Tumor sizes were similar in the CN and Ki-67+ groups (P = 0.32). Median LPFS was 10 versus 16 months for Ki-67+ and CN groups, and 1-year LPFS was 34 and 75 %, respectively (P = 0.003). Median OS was 20 and 46 months (P = 0.12), and median DSS was 20 and 68 months (P = 0.01) for the Ki-67 + and CN groups, respectively. Identification of Ki-67+ tumor cells more than tripled the risk of death from cancer [hazard ratio (HR) = 3.65; 95 % confidence interval (95 % CI), 1.34-9.95; P = 0.01] and tripled the risk of local tumor progression (LTP) (HR = 3.01; 95 % CI, 1.39-6.49; P = 0.005). Conclusions. Ki-67+ tumor cells on the electrode after pulmonary tumor RF ablation is an independent predictor of LTP, shorter LPFS, and DSS.

AB - Background. The objective of this work was to evaluate the feasibility of histopathological analysis of tissue extracted on multitined electrodes and assess whether tissue characteristics can be used as biomarkers of oncologic outcomes after lung tumor radiofrequency (RF) ablation. Methods. Treatment-related data regarding RF ablation of lung malignancies at our institution was collected using a Health Insurance Portability and Accountability Act-compliant ablation database. Institutional review board waiver was obtained for this study. Immunohistochemical analysis of tissue extracted from the electrodes after lung tumor RF ablation was performed for proliferation (Ki-67) and apoptosis (caspase-3). Patient, tumor demographics, and ablation parameters were recorded. Local tumor progression- free survival (LPFS), disease-specific survival (DSS), and overall survival (OS) were assessed using Kaplan- Meier methodology. Multivariate analysis determined factors affecting these oncological outcomes. Results. A total of 47 lung tumors in 42 patients were ablated; 30 specimens were classified as coagulation necrosis (CN) and 17 as Ki-67-positive (+) tumor cells (viable). Tumor sizes were similar in the CN and Ki-67+ groups (P = 0.32). Median LPFS was 10 versus 16 months for Ki-67+ and CN groups, and 1-year LPFS was 34 and 75 %, respectively (P = 0.003). Median OS was 20 and 46 months (P = 0.12), and median DSS was 20 and 68 months (P = 0.01) for the Ki-67 + and CN groups, respectively. Identification of Ki-67+ tumor cells more than tripled the risk of death from cancer [hazard ratio (HR) = 3.65; 95 % confidence interval (95 % CI), 1.34-9.95; P = 0.01] and tripled the risk of local tumor progression (LTP) (HR = 3.01; 95 % CI, 1.39-6.49; P = 0.005). Conclusions. Ki-67+ tumor cells on the electrode after pulmonary tumor RF ablation is an independent predictor of LTP, shorter LPFS, and DSS.

UR - http://www.scopus.com/inward/record.url?scp=84892792727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892792727&partnerID=8YFLogxK

U2 - 10.1245/s10434-013-3140-1

DO - 10.1245/s10434-013-3140-1

M3 - Article

C2 - 23897007

AN - SCOPUS:84892792727

VL - 20

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 3 SUPPL.

ER -